||EPS - Basic
||Market Cap (m)
Real-Time news about Bayer Ord (London Stock Exchange): 0 recent articles
|Bayer Ord Daily Update: Bayer Ord is listed in the Chemicals sector of the London Stock Exchange with ticker BYR. The last closing price for Bayer Ord was 55.93 €.|
Bayer Ord has a 4 week average price of - and a 12 week average price of -.
The 1 year high share price is - while the 1 year low share price is currently -.
There are currently 764,334,705 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Bayer Ord is £42,749,240,050.65.
|grupo guitarlumber: Bayer "overweight," target price raised
Friday, October 26, 2007 8:49:24 AM ET
J.P. Morgan Securities
LONDON, October 26 (newratings.com) - Analysts at JP Morgan reiterate their "overweight" rating on Bayer AG (BAY.ETR), while raising their estimates for the company. The 12-month target price has been raised from 70 to 73.
In a research note published this morning, the analysts mention that there is a 60% probability of the company's Rivaroxaban product achieving peak sales of 5 billion. Bayer's share price is expected to be supported by the improved outlook for the Consumer Health division, oral contraceptives and Kogenate margins, the analysts say. The EPS estimates for 2007 and 2008 have been raised from 3.81 to 3.82 and from 4.19 to 4.21, respectively.|
|ariane: Bayer initiated with "outperform"
Friday, September 14, 2007 10:21:29 AM ET
LONDON, September 14 (newratings.com) - Analyst Richard Vosser of Bear Stearns reinitiates coverage of Bayer AG (BAY.ETR) with an "outperform" rating. The target price is set to 75.
In a research note published this morning, the analyst mentions that the company's Healthcare business is expected to generate 18.9% EPS growth in 2007-2011 and is unlikely to reach an earnings trough up to 2015. Despite the high quality of the Healthcare business, Bayer's share price reflects the value of this business in-line with that of the European large-cap pharma peers, the analyst says. While Xarelto has the potential to become a multi-billion euro product over the next ten years, Nexavar may become a blockbuster in liver cancer, Bear Stearns adds.|
|ariane: Bayer "buy"
Tuesday, September 04, 2007 7:19:03 AM ET
Dresdner Kleinwort Wasser.
LONDON, September 4 (newratings.com) - Analyst Tero Weckroth of Dresdner Kleinwort maintains his "buy" rating on Bayer (BAY.ETR). The target price is set to 67.
In a research note published this morning, the analyst mentions that the company's recent management roadshow was encouraging. Despite the 43% appreciation in Bayer's share price year-to-date, the current valuation of the company's stock is attractive, the analyst adds.|
Bayer Ord share price data is direct from the London Stock Exchange